A compound, named SRI-KH001 or Kakeromycin as a drug candidate for anti-fungi at L1 stage.
A new chemical entity related to SRI-KH001, also effective to pathogenic fungi.
Under validation of novelty of 20 anti-fungi producing strains.
Total synthesis, chemical modification and lead optimization of SRI-KH001
- Collaboration with NITE, National Institute of Technology and Evaluation
- Providing novel drug seeds by executing commissioned screening studies
- Successive generation of anti-fungi drugs
- Execution of screening of anti-virus drugs by use of our HTS technology that can be applied to disease types of virus, cancer, immune system, etc.